First leishmaniasis vaccine enters phase one trial as disease spreads to US
A phase one clinical trial is launching for the first vaccine designed to prevent leishmaniasis, a disfiguring skin disease transmitted by sand flies. The vaccine, developed by researchers at The Ohio State University, has successfully passed FDA safety reviews for human testing.
Why it matters
Leishmaniasis affects millions globally and is increasingly appearing in the United States, making this vaccine a critical development in public health.
by Emily Caldwell, The Ohio State University
The article reports on scientific progress and clinical trial milestones without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in